Vaccine 2015-08-20

Brazilian meningococcal C conjugate vaccine: Scaling up studies.

Renata Chagas Bastos, Iaralice Medeiros de Souza, Milton Neto da Silva, Flavia de Paiva Silva, Elza Scott Figueira, Maria de Lurdes Leal, Ellen Jessouroun, José Godinho da Silva, Ricardo de Andrade Medronho, Ivna Alana Freitas Brasileiro da Silveira

Index: Vaccine 33 , 4281-7, (2015)

Full Text: HTML

Abstract

Several outbreaks caused by Neisseria meningitidis group C have been occurred in different regions of Brazil. A conjugate vaccine for Neisseria meningitidis was produced by chemical linkage between periodate-oxidized meningococcal C polysaccharide and hydrazide-activated monomeric tetanus toxoid via a modified reductive amination conjugation method. Vaccine safety and immunogenicity tested in Phase I and II trials showed satisfactory results. Before starting Phase III trials, vaccine production was scaled up to obtain industrial lots under Good Manufacture Practices (GMP). Comparative analysis between data obtained from industrial and pilot scales of the meningococcal C conjugate bulk showed similar execution times in the scaling up production process without significant losses or alterations in the quality attributes of purified compounds. In conclusion, scale up was considered satisfactory and the Brazilian meningococcal conjugate vaccine production aiming to perform Phase III trials is feasible. Copyright © 2015 Elsevier Ltd. All rights reserved.